View ValuationiXensor 将来の成長Future 基準チェック /06現在、 iXensorの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長20.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$37m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$37m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m (NT$27m revenue, or US$852k). Market cap is less than US$10m (NT$276.2m market cap, or US$8.76m).Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).お知らせ • Mar 03iXensor Co., Ltd., Annual General Meeting, May 20, 2026iXensor Co., Ltd., Annual General Meeting, May 20, 2026, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Market cap is less than US$10m (NT$239.2m market cap, or US$7.62m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Minor Risk Market cap is less than US$100m (NT$352.2m market cap, or US$11.2m).New Risk • Aug 17New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$16m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-NT$16m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$25m revenue, or US$818k). Market cap is less than US$10m (NT$233.3m market cap, or US$7.77m).お知らせ • Mar 07iXensor Co., Ltd., Annual General Meeting, May 20, 2025iXensor Co., Ltd., Annual General Meeting, May 20, 2025, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$197.8m market cap, or US$6.01m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$513k). Market cap is less than US$10m (NT$210.1m market cap, or US$6.37m).New Risk • Jan 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$172.1m market cap, or US$5.23m). Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).New Risk • Aug 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$10m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$525k). Market cap is less than US$10m (NT$230.4m market cap, or US$7.15m).New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$644k). Market cap is less than US$10m (NT$319.8m market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).New Risk • May 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$307.2m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$645k). Market cap is less than US$10m (NT$307.2m market cap, or US$9.48m).Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Mar 19iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$450.4m market cap, or US$14.2m).New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$510.7m market cap, or US$16.2m).New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$551.3m market cap, or US$17.2m).Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).お知らせ • Apr 16iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022.お知らせ • Dec 23iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of ConcerniXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.分析記事 • Mar 24Will iXensor (GTSM:6734) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Feb 27New 90-day low: NT$19.05The company is down 3.0% from its price of NT$19.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period.分析記事 • Dec 10Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Nov 04New 90-day low: NT$19.45The company is down 10.0% from its price of NT$21.50 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 12% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、iXensor は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6734 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202527-47-37-37N/A9/30/202526-46-33-33N/A6/30/202525-45-29-28N/A3/31/202522-46-35-34N/A12/31/202419-47-42-40N/A9/30/202418-52-46-44N/A6/30/202417-57-50-48N/A3/31/202419-60-49-47N/A12/31/202321-63-48-46N/A9/30/202329-57-44-43N/A6/30/202337-52-41-39N/A3/31/202371-28-17-16N/A12/31/2022105-578N/A9/30/2022101-801N/A6/30/202297-11-7-6N/A3/31/202261-42-40-39N/A12/31/202125-73-74-72N/A9/30/202119-81-73-71N/A6/30/202114-90-73-71N/A3/31/202115-83-66-64N/A12/31/202016-77-59-57N/A9/30/202019-88-73-72N/A6/30/202022-99-88-87N/A3/31/202026-102-94-92N/A12/31/201930-105-100-97N/A9/30/201927-103N/A-97N/A6/30/201924-101N/A-98N/A3/31/201918-104N/A-103N/A12/31/201811-108N/A-108N/A12/31/201715-108N/A-111N/A12/31/20160-95N/A-93N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6734の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6734の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6734の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6734の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6734の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6734の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 10:58終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋iXensor Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$37m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$37m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Revenue is less than US$1m (NT$27m revenue, or US$852k). Market cap is less than US$10m (NT$276.2m market cap, or US$8.76m).
Reported Earnings • Apr 22Full year 2025 earnings released: NT$1.37 loss per share (vs NT$2.05 loss in FY 2024)Full year 2025 results: NT$1.37 loss per share. Revenue: NT$26.9m (up 38% from FY 2024). Net loss: NT$47.0m (flat on FY 2024).
お知らせ • Mar 03iXensor Co., Ltd., Annual General Meeting, May 20, 2026iXensor Co., Ltd., Annual General Meeting, May 20, 2026, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Market cap is less than US$10m (NT$239.2m market cap, or US$7.62m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-NT$16m). Revenue is less than US$1m (NT$25m revenue, or US$784k). Minor Risk Market cap is less than US$100m (NT$352.2m market cap, or US$11.2m).
New Risk • Aug 17New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$16m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$29m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-NT$16m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$25m revenue, or US$818k). Market cap is less than US$10m (NT$233.3m market cap, or US$7.77m).
お知らせ • Mar 07iXensor Co., Ltd., Annual General Meeting, May 20, 2025iXensor Co., Ltd., Annual General Meeting, May 20, 2025, at 10:00 Taipei Standard Time. Location: 1 floor no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$197.8m market cap, or US$6.01m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-NT$10m). Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Revenue is less than US$1m (NT$17m revenue, or US$513k). Market cap is less than US$10m (NT$210.1m market cap, or US$6.37m).
New Risk • Jan 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 40% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$514k). Market cap is less than US$10m (NT$172.1m market cap, or US$5.23m). Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).
New Risk • Aug 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -NT$10m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$50m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-NT$10m). Revenue is less than US$1m (NT$17m revenue, or US$525k). Market cap is less than US$10m (NT$230.4m market cap, or US$7.15m).
New Risk • May 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$644k). Market cap is less than US$10m (NT$319.8m market cap, or US$9.86m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
New Risk • May 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$307.2m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$48m free cash flow). Revenue is less than US$1m (NT$21m revenue, or US$645k). Market cap is less than US$10m (NT$307.2m market cap, or US$9.48m).
Reported Earnings • May 05Full year 2023 earnings released: NT$1.15 loss per share (vs NT$0.09 loss in FY 2022)Full year 2023 results: NT$1.15 loss per share (further deteriorated from NT$0.09 loss in FY 2022). Revenue: NT$20.9m (down 80% from FY 2022). Net loss: NT$63.2m (loss widened NT$58.3m from FY 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Mar 19iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024iXensor Co., Ltd., Annual General Meeting, Jun 03, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$450.4m market cap, or US$14.2m).
New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$510.7m market cap, or US$16.2m).
New Risk • Aug 14New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$41m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$41m free cash flow). Minor Risks Revenue is less than US$5m (NT$37m revenue, or US$1.2m). Market cap is less than US$100m (NT$551.3m market cap, or US$17.2m).
Reported Earnings • Aug 17First half 2022 earnings released: EPS: NT$0.23 (vs NT$0.95 loss in 1H 2021)First half 2022 results: EPS: NT$0.23 (up from NT$0.95 loss in 1H 2021). Revenue: NT$79.3m (up NT$72.1m from 1H 2021). Net income: NT$12.5m (up NT$62.1m from 1H 2021). Profit margin: 16% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 02Full year 2021 earnings released: NT$1.40 loss per share (vs NT$1.56 loss in FY 2020)Full year 2021 results: NT$1.40 loss per share (up from NT$1.56 loss in FY 2020). Revenue: NT$24.8m (up 56% from FY 2020). Net loss: NT$73.1m (loss narrowed 4.6% from FY 2020).
お知らせ • Apr 16iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022iXensor Co., Ltd., Annual General Meeting, Jun 30, 2022.
お知らせ • Dec 23iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of ConcerniXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
分析記事 • Mar 24Will iXensor (GTSM:6734) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Feb 27New 90-day low: NT$19.05The company is down 3.0% from its price of NT$19.70 on 27 November 2020. The Taiwanese market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 4.0% over the same period.
分析記事 • Dec 10Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Nov 04New 90-day low: NT$19.45The company is down 10.0% from its price of NT$21.50 on 06 August 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 12% over the same period.